nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentazocine—EBP—Raloxifene—breast cancer	0.32	0.421	CbGbCtD
Pentazocine—EBP—Tamoxifen—breast cancer	0.211	0.278	CbGbCtD
Pentazocine—SIGMAR1—Raloxifene—breast cancer	0.137	0.181	CbGbCtD
Pentazocine—SIGMAR1—Tamoxifen—breast cancer	0.0907	0.12	CbGbCtD
Pentazocine—EBP—uterus—breast cancer	0.00136	0.158	CbGeAlD
Pentazocine—EBP—Azacitidine—Gemcitabine—breast cancer	0.00133	1	CbGdCrCtD
Pentazocine—EBP—female reproductive system—breast cancer	0.00122	0.142	CbGeAlD
Pentazocine—EBP—endocrine gland—breast cancer	0.00103	0.121	CbGeAlD
Pentazocine—SIGMAR1—mammary gland—breast cancer	0.000795	0.0929	CbGeAlD
Pentazocine—SIGMAR1—nipple—breast cancer	0.000658	0.0768	CbGeAlD
Pentazocine—OPRK1—female reproductive system—breast cancer	0.00056	0.0654	CbGeAlD
Pentazocine—SIGMAR1—endometrium—breast cancer	0.000397	0.0464	CbGeAlD
Pentazocine—SIGMAR1—uterus—breast cancer	0.000366	0.0427	CbGeAlD
Pentazocine—SIGMAR1—pituitary gland—breast cancer	0.000359	0.042	CbGeAlD
Pentazocine—SIGMAR1—adipose tissue—breast cancer	0.000358	0.0418	CbGeAlD
Pentazocine—OPRM1—endocrine gland—breast cancer	0.000337	0.0394	CbGeAlD
Pentazocine—SIGMAR1—adrenal gland—breast cancer	0.000321	0.0375	CbGeAlD
Pentazocine—SIGMAR1—bone marrow—breast cancer	0.000311	0.0363	CbGeAlD
Pentazocine—SIGMAR1—female gonad—breast cancer	0.000299	0.035	CbGeAlD
Pentazocine—SIGMAR1—lymph node—breast cancer	0.000192	0.0225	CbGeAlD
Pentazocine—Headache—Goserelin—breast cancer	0.000148	0.000844	CcSEcCtD
Pentazocine—Face oedema—Doxorubicin—breast cancer	0.000148	0.000844	CcSEcCtD
Pentazocine—Decreased appetite—Gemcitabine—breast cancer	0.000148	0.000843	CcSEcCtD
Pentazocine—Chills—Capecitabine—breast cancer	0.000147	0.000842	CcSEcCtD
Pentazocine—Nausea—Tamoxifen—breast cancer	0.000147	0.000838	CcSEcCtD
Pentazocine—Abdominal discomfort—Methotrexate—breast cancer	0.000146	0.000836	CcSEcCtD
Pentazocine—Constipation—Gemcitabine—breast cancer	0.000145	0.000829	CcSEcCtD
Pentazocine—Decreased appetite—Fluorouracil—breast cancer	0.000145	0.000829	CcSEcCtD
Pentazocine—Dry mouth—Paclitaxel—breast cancer	0.000145	0.000828	CcSEcCtD
Pentazocine—Asthenia—Thiotepa—breast cancer	0.000145	0.000827	CcSEcCtD
Pentazocine—Diarrhoea—Vinorelbine—breast cancer	0.000145	0.000826	CcSEcCtD
Pentazocine—Dysgeusia—Docetaxel—breast cancer	0.000145	0.000826	CcSEcCtD
Pentazocine—Nausea—Melphalan—breast cancer	0.000144	0.000821	CcSEcCtD
Pentazocine—Feeling abnormal—Irinotecan—breast cancer	0.000144	0.00082	CcSEcCtD
Pentazocine—Feeling abnormal—Mitoxantrone—breast cancer	0.000144	0.00082	CcSEcCtD
Pentazocine—Confusional state—Paclitaxel—breast cancer	0.000143	0.000819	CcSEcCtD
Pentazocine—Pruritus—Thiotepa—breast cancer	0.000143	0.000816	CcSEcCtD
Pentazocine—Anaphylactic shock—Paclitaxel—breast cancer	0.000142	0.000812	CcSEcCtD
Pentazocine—Muscle spasms—Docetaxel—breast cancer	0.000142	0.000811	CcSEcCtD
Pentazocine—Eosinophilia—Epirubicin—breast cancer	0.000141	0.000808	CcSEcCtD
Pentazocine—Nausea—Goserelin—breast cancer	0.00014	0.000801	CcSEcCtD
Pentazocine—Dysgeusia—Capecitabine—breast cancer	0.00014	0.000799	CcSEcCtD
Pentazocine—Feeling abnormal—Gemcitabine—breast cancer	0.00014	0.000799	CcSEcCtD
Pentazocine—Shock—Paclitaxel—breast cancer	0.00014	0.000799	CcSEcCtD
Pentazocine—Dizziness—Vinorelbine—breast cancer	0.00014	0.000798	CcSEcCtD
Pentazocine—Tachycardia—Paclitaxel—breast cancer	0.000139	0.000792	CcSEcCtD
Pentazocine—Diarrhoea—Thiotepa—breast cancer	0.000138	0.000789	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Doxorubicin—breast cancer	0.000138	0.000787	CcSEcCtD
Pentazocine—Feeling abnormal—Fluorouracil—breast cancer	0.000138	0.000786	CcSEcCtD
Pentazocine—Muscle spasms—Capecitabine—breast cancer	0.000137	0.000785	CcSEcCtD
Pentazocine—Hyperhidrosis—Paclitaxel—breast cancer	0.000137	0.000785	CcSEcCtD
Pentazocine—Anorexia—Paclitaxel—breast cancer	0.000135	0.000774	CcSEcCtD
Pentazocine—Vision blurred—Capecitabine—breast cancer	0.000135	0.000769	CcSEcCtD
Pentazocine—Vomiting—Vinorelbine—breast cancer	0.000134	0.000768	CcSEcCtD
Pentazocine—Tremor—Capecitabine—breast cancer	0.000134	0.000765	CcSEcCtD
Pentazocine—Dizziness—Thiotepa—breast cancer	0.000133	0.000762	CcSEcCtD
Pentazocine—Dermatitis—Vinorelbine—breast cancer	0.000133	0.00076	CcSEcCtD
Pentazocine—Hypotension—Paclitaxel—breast cancer	0.000133	0.000759	CcSEcCtD
Pentazocine—Headache—Vinorelbine—breast cancer	0.000132	0.000756	CcSEcCtD
Pentazocine—Syncope—Docetaxel—breast cancer	0.000132	0.000756	CcSEcCtD
Pentazocine—Eosinophilia—Doxorubicin—breast cancer	0.000131	0.000748	CcSEcCtD
Pentazocine—Sweating—Methotrexate—breast cancer	0.000131	0.000746	CcSEcCtD
Pentazocine—Loss of consciousness—Docetaxel—breast cancer	0.00013	0.000741	CcSEcCtD
Pentazocine—Insomnia—Paclitaxel—breast cancer	0.000129	0.000734	CcSEcCtD
Pentazocine—Vertigo—Capecitabine—breast cancer	0.000128	0.000733	CcSEcCtD
Pentazocine—Hypersensitivity—Irinotecan—breast cancer	0.000128	0.000733	CcSEcCtD
Pentazocine—Hypersensitivity—Mitoxantrone—breast cancer	0.000128	0.000733	CcSEcCtD
Pentazocine—Vomiting—Thiotepa—breast cancer	0.000128	0.000733	CcSEcCtD
Pentazocine—Syncope—Capecitabine—breast cancer	0.000128	0.000732	CcSEcCtD
Pentazocine—Paraesthesia—Paclitaxel—breast cancer	0.000128	0.000729	CcSEcCtD
Pentazocine—Hypertension—Docetaxel—breast cancer	0.000127	0.000728	CcSEcCtD
Pentazocine—Dermatitis—Thiotepa—breast cancer	0.000127	0.000726	CcSEcCtD
Pentazocine—Agranulocytosis—Methotrexate—breast cancer	0.000127	0.000726	CcSEcCtD
Pentazocine—Dyspnoea—Paclitaxel—breast cancer	0.000127	0.000724	CcSEcCtD
Pentazocine—Headache—Thiotepa—breast cancer	0.000126	0.000722	CcSEcCtD
Pentazocine—Somnolence—Paclitaxel—breast cancer	0.000126	0.000722	CcSEcCtD
Pentazocine—Loss of consciousness—Capecitabine—breast cancer	0.000126	0.000718	CcSEcCtD
Pentazocine—Nausea—Vinorelbine—breast cancer	0.000126	0.000717	CcSEcCtD
Pentazocine—Asthenia—Mitoxantrone—breast cancer	0.000125	0.000714	CcSEcCtD
Pentazocine—Asthenia—Irinotecan—breast cancer	0.000125	0.000714	CcSEcCtD
Pentazocine—Decreased appetite—Paclitaxel—breast cancer	0.000124	0.000706	CcSEcCtD
Pentazocine—Hypertension—Capecitabine—breast cancer	0.000123	0.000705	CcSEcCtD
Pentazocine—Hypersensitivity—Fluorouracil—breast cancer	0.000123	0.000702	CcSEcCtD
Pentazocine—Dry mouth—Docetaxel—breast cancer	0.000123	0.000702	CcSEcCtD
Pentazocine—Sweating—Epirubicin—breast cancer	0.000122	0.000698	CcSEcCtD
Pentazocine—Asthenia—Gemcitabine—breast cancer	0.000122	0.000696	CcSEcCtD
Pentazocine—Constipation—Paclitaxel—breast cancer	0.000122	0.000694	CcSEcCtD
Pentazocine—Confusional state—Docetaxel—breast cancer	0.000121	0.000694	CcSEcCtD
Pentazocine—Anaphylactic shock—Docetaxel—breast cancer	0.00012	0.000688	CcSEcCtD
Pentazocine—Pruritus—Gemcitabine—breast cancer	0.00012	0.000686	CcSEcCtD
Pentazocine—Nausea—Thiotepa—breast cancer	0.00012	0.000685	CcSEcCtD
Pentazocine—Diarrhoea—Irinotecan—breast cancer	0.000119	0.000681	CcSEcCtD
Pentazocine—Diarrhoea—Mitoxantrone—breast cancer	0.000119	0.000681	CcSEcCtD
Pentazocine—Dry mouth—Capecitabine—breast cancer	0.000119	0.00068	CcSEcCtD
Pentazocine—Agranulocytosis—Epirubicin—breast cancer	0.000119	0.000679	CcSEcCtD
Pentazocine—Shock—Docetaxel—breast cancer	0.000119	0.000677	CcSEcCtD
Pentazocine—Pruritus—Fluorouracil—breast cancer	0.000118	0.000675	CcSEcCtD
Pentazocine—Visual impairment—Methotrexate—breast cancer	0.000118	0.000673	CcSEcCtD
Pentazocine—Confusional state—Capecitabine—breast cancer	0.000118	0.000672	CcSEcCtD
Pentazocine—Tachycardia—Docetaxel—breast cancer	0.000118	0.000672	CcSEcCtD
Pentazocine—Feeling abnormal—Paclitaxel—breast cancer	0.000117	0.000669	CcSEcCtD
Pentazocine—Diarrhoea—Gemcitabine—breast cancer	0.000116	0.000664	CcSEcCtD
Pentazocine—Erythema multiforme—Methotrexate—breast cancer	0.000116	0.00066	CcSEcCtD
Pentazocine—Dizziness—Irinotecan—breast cancer	0.000115	0.000658	CcSEcCtD
Pentazocine—Anorexia—Docetaxel—breast cancer	0.000115	0.000656	CcSEcCtD
Pentazocine—Shock—Capecitabine—breast cancer	0.000115	0.000656	CcSEcCtD
Pentazocine—Diarrhoea—Fluorouracil—breast cancer	0.000114	0.000652	CcSEcCtD
Pentazocine—Tinnitus—Methotrexate—breast cancer	0.000114	0.000651	CcSEcCtD
Pentazocine—Tachycardia—Capecitabine—breast cancer	0.000114	0.00065	CcSEcCtD
Pentazocine—Sweating—Doxorubicin—breast cancer	0.000113	0.000646	CcSEcCtD
Pentazocine—Hyperhidrosis—Capecitabine—breast cancer	0.000113	0.000644	CcSEcCtD
Pentazocine—Hypotension—Docetaxel—breast cancer	0.000113	0.000643	CcSEcCtD
Pentazocine—Anorexia—Capecitabine—breast cancer	0.000111	0.000635	CcSEcCtD
Pentazocine—Vomiting—Mitoxantrone—breast cancer	0.000111	0.000633	CcSEcCtD
Pentazocine—Vomiting—Irinotecan—breast cancer	0.000111	0.000633	CcSEcCtD
Pentazocine—Dizziness—Fluorouracil—breast cancer	0.00011	0.000631	CcSEcCtD
Pentazocine—Visual impairment—Epirubicin—breast cancer	0.00011	0.00063	CcSEcCtD
Pentazocine—Agranulocytosis—Doxorubicin—breast cancer	0.00011	0.000628	CcSEcCtD
Pentazocine—Dermatitis—Mitoxantrone—breast cancer	0.00011	0.000627	CcSEcCtD
Pentazocine—Dermatitis—Irinotecan—breast cancer	0.00011	0.000627	CcSEcCtD
Pentazocine—Chills—Methotrexate—breast cancer	0.00011	0.000626	CcSEcCtD
Pentazocine—Headache—Irinotecan—breast cancer	0.000109	0.000624	CcSEcCtD
Pentazocine—Headache—Mitoxantrone—breast cancer	0.000109	0.000624	CcSEcCtD
Pentazocine—Hypotension—Capecitabine—breast cancer	0.000109	0.000623	CcSEcCtD
Pentazocine—Insomnia—Docetaxel—breast cancer	0.000109	0.000622	CcSEcCtD
Pentazocine—Paraesthesia—Docetaxel—breast cancer	0.000108	0.000618	CcSEcCtD
Pentazocine—Erythema multiforme—Epirubicin—breast cancer	0.000108	0.000618	CcSEcCtD
Pentazocine—Vomiting—Gemcitabine—breast cancer	0.000108	0.000617	CcSEcCtD
Pentazocine—Dyspnoea—Docetaxel—breast cancer	0.000107	0.000614	CcSEcCtD
Pentazocine—Somnolence—Docetaxel—breast cancer	0.000107	0.000612	CcSEcCtD
Pentazocine—Dermatitis—Gemcitabine—breast cancer	0.000107	0.000611	CcSEcCtD
Pentazocine—Tinnitus—Epirubicin—breast cancer	0.000107	0.000609	CcSEcCtD
Pentazocine—Headache—Gemcitabine—breast cancer	0.000106	0.000608	CcSEcCtD
Pentazocine—Flushing—Epirubicin—breast cancer	0.000106	0.000606	CcSEcCtD
Pentazocine—Vomiting—Fluorouracil—breast cancer	0.000106	0.000606	CcSEcCtD
Pentazocine—Insomnia—Capecitabine—breast cancer	0.000105	0.000603	CcSEcCtD
Pentazocine—Dermatitis—Fluorouracil—breast cancer	0.000105	0.000601	CcSEcCtD
Pentazocine—Paraesthesia—Capecitabine—breast cancer	0.000105	0.000598	CcSEcCtD
Pentazocine—Decreased appetite—Docetaxel—breast cancer	0.000105	0.000598	CcSEcCtD
Pentazocine—Hypersensitivity—Paclitaxel—breast cancer	0.000105	0.000598	CcSEcCtD
Pentazocine—Headache—Fluorouracil—breast cancer	0.000105	0.000597	CcSEcCtD
Pentazocine—Dysgeusia—Methotrexate—breast cancer	0.000104	0.000595	CcSEcCtD
Pentazocine—Dyspnoea—Capecitabine—breast cancer	0.000104	0.000594	CcSEcCtD
Pentazocine—Nausea—Irinotecan—breast cancer	0.000104	0.000591	CcSEcCtD
Pentazocine—Nausea—Mitoxantrone—breast cancer	0.000104	0.000591	CcSEcCtD
Pentazocine—Constipation—Docetaxel—breast cancer	0.000103	0.000589	CcSEcCtD
Pentazocine—Chills—Epirubicin—breast cancer	0.000103	0.000586	CcSEcCtD
Pentazocine—Visual impairment—Doxorubicin—breast cancer	0.000102	0.000583	CcSEcCtD
Pentazocine—Asthenia—Paclitaxel—breast cancer	0.000102	0.000583	CcSEcCtD
Pentazocine—Decreased appetite—Capecitabine—breast cancer	0.000101	0.000579	CcSEcCtD
Pentazocine—Nausea—Gemcitabine—breast cancer	0.000101	0.000576	CcSEcCtD
Pentazocine—Pruritus—Paclitaxel—breast cancer	0.000101	0.000574	CcSEcCtD
Pentazocine—Vision blurred—Methotrexate—breast cancer	0.0001	0.000573	CcSEcCtD
Pentazocine—Erythema multiforme—Doxorubicin—breast cancer	0.0001	0.000572	CcSEcCtD
Pentazocine—Constipation—Capecitabine—breast cancer	9.97e-05	0.00057	CcSEcCtD
Pentazocine—Feeling abnormal—Docetaxel—breast cancer	9.93e-05	0.000567	CcSEcCtD
Pentazocine—Nausea—Fluorouracil—breast cancer	9.91e-05	0.000566	CcSEcCtD
Pentazocine—Tinnitus—Doxorubicin—breast cancer	9.87e-05	0.000564	CcSEcCtD
Pentazocine—Flushing—Doxorubicin—breast cancer	9.82e-05	0.000561	CcSEcCtD
Pentazocine—Dysgeusia—Epirubicin—breast cancer	9.75e-05	0.000557	CcSEcCtD
Pentazocine—Diarrhoea—Paclitaxel—breast cancer	9.72e-05	0.000556	CcSEcCtD
Pentazocine—Feeling abnormal—Capecitabine—breast cancer	9.61e-05	0.000549	CcSEcCtD
Pentazocine—Muscle spasms—Epirubicin—breast cancer	9.57e-05	0.000547	CcSEcCtD
Pentazocine—Vertigo—Methotrexate—breast cancer	9.56e-05	0.000546	CcSEcCtD
Pentazocine—Chills—Doxorubicin—breast cancer	9.5e-05	0.000542	CcSEcCtD
Pentazocine—Dizziness—Paclitaxel—breast cancer	9.4e-05	0.000537	CcSEcCtD
Pentazocine—Vision blurred—Epirubicin—breast cancer	9.38e-05	0.000536	CcSEcCtD
Pentazocine—Agitation—Epirubicin—breast cancer	9.15e-05	0.000523	CcSEcCtD
Pentazocine—Vomiting—Paclitaxel—breast cancer	9.04e-05	0.000516	CcSEcCtD
Pentazocine—Dysgeusia—Doxorubicin—breast cancer	9.02e-05	0.000515	CcSEcCtD
Pentazocine—Dermatitis—Paclitaxel—breast cancer	8.95e-05	0.000511	CcSEcCtD
Pentazocine—Vertigo—Epirubicin—breast cancer	8.95e-05	0.000511	CcSEcCtD
Pentazocine—Syncope—Epirubicin—breast cancer	8.93e-05	0.00051	CcSEcCtD
Pentazocine—Headache—Paclitaxel—breast cancer	8.9e-05	0.000509	CcSEcCtD
Pentazocine—Hypersensitivity—Docetaxel—breast cancer	8.88e-05	0.000507	CcSEcCtD
Pentazocine—Muscle spasms—Doxorubicin—breast cancer	8.86e-05	0.000506	CcSEcCtD
Pentazocine—Confusional state—Methotrexate—breast cancer	8.76e-05	0.0005	CcSEcCtD
Pentazocine—Loss of consciousness—Epirubicin—breast cancer	8.75e-05	0.0005	CcSEcCtD
Pentazocine—Anaphylactic shock—Methotrexate—breast cancer	8.68e-05	0.000496	CcSEcCtD
Pentazocine—Vision blurred—Doxorubicin—breast cancer	8.68e-05	0.000496	CcSEcCtD
Pentazocine—Asthenia—Docetaxel—breast cancer	8.64e-05	0.000494	CcSEcCtD
Pentazocine—Hypertension—Epirubicin—breast cancer	8.6e-05	0.000491	CcSEcCtD
Pentazocine—Hypersensitivity—Capecitabine—breast cancer	8.59e-05	0.000491	CcSEcCtD
Pentazocine—Pruritus—Docetaxel—breast cancer	8.52e-05	0.000487	CcSEcCtD
Pentazocine—Agitation—Doxorubicin—breast cancer	8.47e-05	0.000484	CcSEcCtD
Pentazocine—Nausea—Paclitaxel—breast cancer	8.44e-05	0.000482	CcSEcCtD
Pentazocine—Hyperhidrosis—Methotrexate—breast cancer	8.39e-05	0.00048	CcSEcCtD
Pentazocine—Asthenia—Capecitabine—breast cancer	8.37e-05	0.000478	CcSEcCtD
Pentazocine—Dry mouth—Epirubicin—breast cancer	8.29e-05	0.000474	CcSEcCtD
Pentazocine—Vertigo—Doxorubicin—breast cancer	8.28e-05	0.000473	CcSEcCtD
Pentazocine—Anorexia—Methotrexate—breast cancer	8.28e-05	0.000473	CcSEcCtD
Pentazocine—Syncope—Doxorubicin—breast cancer	8.26e-05	0.000472	CcSEcCtD
Pentazocine—Pruritus—Capecitabine—breast cancer	8.25e-05	0.000471	CcSEcCtD
Pentazocine—Diarrhoea—Docetaxel—breast cancer	8.24e-05	0.000471	CcSEcCtD
Pentazocine—Confusional state—Epirubicin—breast cancer	8.19e-05	0.000468	CcSEcCtD
Pentazocine—Anaphylactic shock—Epirubicin—breast cancer	8.13e-05	0.000464	CcSEcCtD
Pentazocine—Hypotension—Methotrexate—breast cancer	8.11e-05	0.000463	CcSEcCtD
Pentazocine—Loss of consciousness—Doxorubicin—breast cancer	8.1e-05	0.000463	CcSEcCtD
Pentazocine—Shock—Epirubicin—breast cancer	7.99e-05	0.000457	CcSEcCtD
Pentazocine—Diarrhoea—Capecitabine—breast cancer	7.98e-05	0.000456	CcSEcCtD
Pentazocine—Dizziness—Docetaxel—breast cancer	7.97e-05	0.000455	CcSEcCtD
Pentazocine—Hypertension—Doxorubicin—breast cancer	7.95e-05	0.000454	CcSEcCtD
Pentazocine—Tachycardia—Epirubicin—breast cancer	7.93e-05	0.000453	CcSEcCtD
Pentazocine—Hyperhidrosis—Epirubicin—breast cancer	7.86e-05	0.000449	CcSEcCtD
Pentazocine—Insomnia—Methotrexate—breast cancer	7.85e-05	0.000449	CcSEcCtD
Pentazocine—Paraesthesia—Methotrexate—breast cancer	7.8e-05	0.000445	CcSEcCtD
Pentazocine—Anorexia—Epirubicin—breast cancer	7.75e-05	0.000442	CcSEcCtD
Pentazocine—Dyspnoea—Methotrexate—breast cancer	7.74e-05	0.000442	CcSEcCtD
Pentazocine—Somnolence—Methotrexate—breast cancer	7.72e-05	0.000441	CcSEcCtD
Pentazocine—Dizziness—Capecitabine—breast cancer	7.71e-05	0.000441	CcSEcCtD
Pentazocine—Dry mouth—Doxorubicin—breast cancer	7.67e-05	0.000438	CcSEcCtD
Pentazocine—Vomiting—Docetaxel—breast cancer	7.66e-05	0.000438	CcSEcCtD
Pentazocine—Hypotension—Epirubicin—breast cancer	7.59e-05	0.000434	CcSEcCtD
Pentazocine—Dermatitis—Docetaxel—breast cancer	7.59e-05	0.000434	CcSEcCtD
Pentazocine—Confusional state—Doxorubicin—breast cancer	7.58e-05	0.000433	CcSEcCtD
Pentazocine—Decreased appetite—Methotrexate—breast cancer	7.55e-05	0.000431	CcSEcCtD
Pentazocine—Headache—Docetaxel—breast cancer	7.55e-05	0.000431	CcSEcCtD
Pentazocine—Anaphylactic shock—Doxorubicin—breast cancer	7.52e-05	0.000429	CcSEcCtD
Pentazocine—Vomiting—Capecitabine—breast cancer	7.42e-05	0.000424	CcSEcCtD
Pentazocine—Shock—Doxorubicin—breast cancer	7.4e-05	0.000423	CcSEcCtD
Pentazocine—Insomnia—Epirubicin—breast cancer	7.35e-05	0.00042	CcSEcCtD
Pentazocine—Dermatitis—Capecitabine—breast cancer	7.35e-05	0.00042	CcSEcCtD
Pentazocine—Tachycardia—Doxorubicin—breast cancer	7.34e-05	0.000419	CcSEcCtD
Pentazocine—Headache—Capecitabine—breast cancer	7.31e-05	0.000417	CcSEcCtD
Pentazocine—Paraesthesia—Epirubicin—breast cancer	7.3e-05	0.000417	CcSEcCtD
Pentazocine—Hyperhidrosis—Doxorubicin—breast cancer	7.27e-05	0.000415	CcSEcCtD
Pentazocine—Dyspnoea—Epirubicin—breast cancer	7.24e-05	0.000414	CcSEcCtD
Pentazocine—Somnolence—Epirubicin—breast cancer	7.22e-05	0.000413	CcSEcCtD
Pentazocine—Anorexia—Doxorubicin—breast cancer	7.17e-05	0.000409	CcSEcCtD
Pentazocine—Nausea—Docetaxel—breast cancer	7.16e-05	0.000409	CcSEcCtD
Pentazocine—Feeling abnormal—Methotrexate—breast cancer	7.16e-05	0.000409	CcSEcCtD
Pentazocine—Decreased appetite—Epirubicin—breast cancer	7.06e-05	0.000404	CcSEcCtD
Pentazocine—Hypotension—Doxorubicin—breast cancer	7.03e-05	0.000401	CcSEcCtD
Pentazocine—Constipation—Epirubicin—breast cancer	6.95e-05	0.000397	CcSEcCtD
Pentazocine—Nausea—Capecitabine—breast cancer	6.93e-05	0.000396	CcSEcCtD
Pentazocine—Insomnia—Doxorubicin—breast cancer	6.8e-05	0.000388	CcSEcCtD
Pentazocine—Paraesthesia—Doxorubicin—breast cancer	6.75e-05	0.000386	CcSEcCtD
Pentazocine—Dyspnoea—Doxorubicin—breast cancer	6.7e-05	0.000383	CcSEcCtD
Pentazocine—Feeling abnormal—Epirubicin—breast cancer	6.7e-05	0.000383	CcSEcCtD
Pentazocine—Somnolence—Doxorubicin—breast cancer	6.68e-05	0.000382	CcSEcCtD
Pentazocine—Decreased appetite—Doxorubicin—breast cancer	6.54e-05	0.000373	CcSEcCtD
Pentazocine—Constipation—Doxorubicin—breast cancer	6.43e-05	0.000367	CcSEcCtD
Pentazocine—Hypersensitivity—Methotrexate—breast cancer	6.4e-05	0.000365	CcSEcCtD
Pentazocine—Asthenia—Methotrexate—breast cancer	6.23e-05	0.000356	CcSEcCtD
Pentazocine—Feeling abnormal—Doxorubicin—breast cancer	6.2e-05	0.000354	CcSEcCtD
Pentazocine—Pruritus—Methotrexate—breast cancer	6.14e-05	0.000351	CcSEcCtD
Pentazocine—Hypersensitivity—Epirubicin—breast cancer	5.99e-05	0.000342	CcSEcCtD
Pentazocine—Diarrhoea—Methotrexate—breast cancer	5.94e-05	0.000339	CcSEcCtD
Pentazocine—Asthenia—Epirubicin—breast cancer	5.83e-05	0.000333	CcSEcCtD
Pentazocine—Pruritus—Epirubicin—breast cancer	5.75e-05	0.000328	CcSEcCtD
Pentazocine—Dizziness—Methotrexate—breast cancer	5.74e-05	0.000328	CcSEcCtD
Pentazocine—Diarrhoea—Epirubicin—breast cancer	5.56e-05	0.000318	CcSEcCtD
Pentazocine—Hypersensitivity—Doxorubicin—breast cancer	5.54e-05	0.000316	CcSEcCtD
Pentazocine—Vomiting—Methotrexate—breast cancer	5.52e-05	0.000315	CcSEcCtD
Pentazocine—Dermatitis—Methotrexate—breast cancer	5.47e-05	0.000312	CcSEcCtD
Pentazocine—Headache—Methotrexate—breast cancer	5.44e-05	0.000311	CcSEcCtD
Pentazocine—Asthenia—Doxorubicin—breast cancer	5.39e-05	0.000308	CcSEcCtD
Pentazocine—Dizziness—Epirubicin—breast cancer	5.37e-05	0.000307	CcSEcCtD
Pentazocine—Pruritus—Doxorubicin—breast cancer	5.32e-05	0.000304	CcSEcCtD
Pentazocine—Vomiting—Epirubicin—breast cancer	5.17e-05	0.000295	CcSEcCtD
Pentazocine—Nausea—Methotrexate—breast cancer	5.16e-05	0.000295	CcSEcCtD
Pentazocine—Diarrhoea—Doxorubicin—breast cancer	5.14e-05	0.000294	CcSEcCtD
Pentazocine—Dermatitis—Epirubicin—breast cancer	5.12e-05	0.000292	CcSEcCtD
Pentazocine—Headache—Epirubicin—breast cancer	5.09e-05	0.000291	CcSEcCtD
Pentazocine—Dizziness—Doxorubicin—breast cancer	4.97e-05	0.000284	CcSEcCtD
Pentazocine—Nausea—Epirubicin—breast cancer	4.83e-05	0.000276	CcSEcCtD
Pentazocine—Vomiting—Doxorubicin—breast cancer	4.78e-05	0.000273	CcSEcCtD
Pentazocine—Dermatitis—Doxorubicin—breast cancer	4.74e-05	0.000271	CcSEcCtD
Pentazocine—Headache—Doxorubicin—breast cancer	4.71e-05	0.000269	CcSEcCtD
Pentazocine—Nausea—Doxorubicin—breast cancer	4.47e-05	0.000255	CcSEcCtD
Pentazocine—OPRD1—Signaling by GPCR—PIK3CB—breast cancer	1.31e-05	0.000234	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PAK1—breast cancer	1.31e-05	0.000233	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—TGFBR2—breast cancer	1.3e-05	0.000232	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—TCF7L2—breast cancer	1.29e-05	0.000229	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—ITPR1—breast cancer	1.28e-05	0.000228	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—AKT2—breast cancer	1.28e-05	0.000228	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—STAT5A—breast cancer	1.27e-05	0.000226	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—ERBB4—breast cancer	1.27e-05	0.000226	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—MMP3—breast cancer	1.27e-05	0.000226	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—PIK3CG—breast cancer	1.27e-05	0.000226	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—PIK3CB—breast cancer	1.27e-05	0.000226	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—SPP1—breast cancer	1.27e-05	0.000226	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CXCL8—breast cancer	1.26e-05	0.000225	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—ERBB3—breast cancer	1.26e-05	0.000223	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—FGFR2—breast cancer	1.25e-05	0.000223	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—HSP90AA1—breast cancer	1.24e-05	0.000221	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—NOTCH2—breast cancer	1.24e-05	0.000221	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—SMAD4—breast cancer	1.23e-05	0.000219	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—PIK3CD—breast cancer	1.23e-05	0.000219	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IGF1R—breast cancer	1.23e-05	0.000218	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—CXCL8—breast cancer	1.22e-05	0.000217	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—IL2—breast cancer	1.21e-05	0.000215	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PRL—breast cancer	1.21e-05	0.000215	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—AGTR1—breast cancer	1.21e-05	0.000215	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—HES1—breast cancer	1.2e-05	0.000214	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—TERT—breast cancer	1.2e-05	0.000214	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PLA2G4A—breast cancer	1.2e-05	0.000213	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—NCOR1—breast cancer	1.2e-05	0.000213	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—STK11—breast cancer	1.19e-05	0.000212	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—ADAM10—breast cancer	1.19e-05	0.000212	CbGpPWpGaD
Pentazocine—EBP—Metabolism—AKT1—breast cancer	1.18e-05	0.000211	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CSF2—breast cancer	1.18e-05	0.00021	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—FGF1—breast cancer	1.18e-05	0.00021	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—RAF1—breast cancer	1.18e-05	0.00021	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PLG—breast cancer	1.18e-05	0.000209	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—NRG1—breast cancer	1.18e-05	0.000209	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—FGFR1—breast cancer	1.17e-05	0.000208	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—H2AFX—breast cancer	1.17e-05	0.000207	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—IL2—breast cancer	1.17e-05	0.000207	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—AKT2—breast cancer	1.16e-05	0.000207	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—E2F1—breast cancer	1.16e-05	0.000206	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—FGF10—breast cancer	1.16e-05	0.000206	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—PIK3CB—breast cancer	1.15e-05	0.000205	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—HIF1A—breast cancer	1.15e-05	0.000205	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—LEP—breast cancer	1.12e-05	0.0002	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—PIK3CD—breast cancer	1.12e-05	0.000199	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PDGFA—breast cancer	1.12e-05	0.000199	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—SPP1—breast cancer	1.11e-05	0.000198	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CAV1—breast cancer	1.11e-05	0.000198	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—CXCL8—breast cancer	1.11e-05	0.000197	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—TGFBR2—breast cancer	1.1e-05	0.000196	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—ERBB3—breast cancer	1.1e-05	0.000196	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—KDR—breast cancer	1.1e-05	0.000196	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—FGFR2—breast cancer	1.1e-05	0.000195	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—ITPR1—breast cancer	1.08e-05	0.000193	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—ERBB4—breast cancer	1.08e-05	0.000191	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—MMP3—breast cancer	1.08e-05	0.000191	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—STAT5A—breast cancer	1.08e-05	0.000191	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—PIK3CB—breast cancer	1.07e-05	0.000191	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—ESR1—breast cancer	1.07e-05	0.000191	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—FN1—breast cancer	1.06e-05	0.000188	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—IL2—breast cancer	1.06e-05	0.000188	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—TERT—breast cancer	1.06e-05	0.000188	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—NFKBIA—breast cancer	1.05e-05	0.000186	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—SMAD4—breast cancer	1.04e-05	0.000185	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—NOTCH1—breast cancer	1.04e-05	0.000184	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IGF1R—breast cancer	1.04e-05	0.000184	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—CXCL8—breast cancer	1.03e-05	0.000183	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—FGFR1—breast cancer	1.02e-05	0.000182	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—HES1—breast cancer	1.02e-05	0.000181	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PIK3CG—breast cancer	1.01e-05	0.00018	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—KIT—breast cancer	1.01e-05	0.00018	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—APC—breast cancer	1.01e-05	0.00018	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PLA2G4A—breast cancer	1.01e-05	0.00018	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—NCOR1—breast cancer	1.01e-05	0.00018	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—HIF1A—breast cancer	1.01e-05	0.000179	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—EGF—breast cancer	1e-05	0.000178	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CSF2—breast cancer	1e-05	0.000178	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—FGF1—breast cancer	1e-05	0.000178	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—RAF1—breast cancer	9.98e-06	0.000177	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—NRG1—breast cancer	9.93e-06	0.000177	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—H2AFX—breast cancer	9.86e-06	0.000175	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—IL2—breast cancer	9.85e-06	0.000175	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—LEP—breast cancer	9.85e-06	0.000175	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—E2F1—breast cancer	9.79e-06	0.000174	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CAV1—breast cancer	9.76e-06	0.000173	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—PIK3CB—breast cancer	9.74e-06	0.000173	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—MAPK3—breast cancer	9.71e-06	0.000173	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—KDR—breast cancer	9.65e-06	0.000172	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—BRAF—breast cancer	9.53e-06	0.000169	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—SPP1—breast cancer	9.41e-06	0.000167	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—ESR1—breast cancer	9.4e-06	0.000167	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CXCL8—breast cancer	9.36e-06	0.000166	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—ERBB3—breast cancer	9.3e-06	0.000165	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—FGFR2—breast cancer	9.29e-06	0.000165	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—FN1—breast cancer	9.29e-06	0.000165	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IGF1—breast cancer	9.28e-06	0.000165	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—AKT2—breast cancer	9.27e-06	0.000165	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—EGFR—breast cancer	9.24e-06	0.000164	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—NFKBIA—breast cancer	9.18e-06	0.000163	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—NOTCH1—breast cancer	9.09e-06	0.000162	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—IL2—breast cancer	8.95e-06	0.000159	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—TERT—breast cancer	8.92e-06	0.000159	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PIK3CD—breast cancer	8.91e-06	0.000158	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PIK3CG—breast cancer	8.89e-06	0.000158	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—APC—breast cancer	8.89e-06	0.000158	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—KIT—breast cancer	8.89e-06	0.000158	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—PIK3CA—breast cancer	8.83e-06	0.000157	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—SERPINE1—breast cancer	8.81e-06	0.000157	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—EGF—breast cancer	8.79e-06	0.000156	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—KRAS—breast cancer	8.72e-06	0.000155	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—FGFR1—breast cancer	8.66e-06	0.000154	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—HIF1A—breast cancer	8.53e-06	0.000152	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—MAPK3—breast cancer	8.51e-06	0.000151	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—NOS3—breast cancer	8.42e-06	0.00015	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—BRAF—breast cancer	8.36e-06	0.000149	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—LEP—breast cancer	8.32e-06	0.000148	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CAV1—breast cancer	8.25e-06	0.000147	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—KDR—breast cancer	8.16e-06	0.000145	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IGF1—breast cancer	8.14e-06	0.000145	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—AKT2—breast cancer	8.13e-06	0.000145	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—EGFR—breast cancer	8.1e-06	0.000144	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—PIK3CA—breast cancer	8.02e-06	0.000143	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—MDM2—breast cancer	7.98e-06	0.000142	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—RAF1—breast cancer	7.96e-06	0.000141	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—ESR1—breast cancer	7.95e-06	0.000141	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—RELA—breast cancer	7.92e-06	0.000141	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—ERBB2—breast cancer	7.87e-06	0.00014	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—FN1—breast cancer	7.85e-06	0.00014	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PIK3CD—breast cancer	7.81e-06	0.000139	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PIK3CB—breast cancer	7.77e-06	0.000138	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—MTOR—breast cancer	7.77e-06	0.000138	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—NFKBIA—breast cancer	7.76e-06	0.000138	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—PIK3CA—breast cancer	7.74e-06	0.000138	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—SERPINE1—breast cancer	7.73e-06	0.000137	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—NOTCH1—breast cancer	7.68e-06	0.000137	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—KRAS—breast cancer	7.65e-06	0.000136	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PIK3CG—breast cancer	7.51e-06	0.000134	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—APC—breast cancer	7.51e-06	0.000134	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—KIT—breast cancer	7.51e-06	0.000134	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CXCL8—breast cancer	7.46e-06	0.000133	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—EGF—breast cancer	7.43e-06	0.000132	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—HRAS—breast cancer	7.42e-06	0.000132	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—NOS3—breast cancer	7.38e-06	0.000131	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CDKN1B—breast cancer	7.29e-06	0.00013	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—AKT1—breast cancer	7.21e-06	0.000128	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—MAPK3—breast cancer	7.19e-06	0.000128	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CASP3—breast cancer	7.14e-06	0.000127	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IL2—breast cancer	7.13e-06	0.000127	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—IL6—breast cancer	7.1e-06	0.000126	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—BRAF—breast cancer	7.06e-06	0.000126	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—PIK3CA—breast cancer	7.03e-06	0.000125	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—MDM2—breast cancer	7e-06	0.000124	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—RAF1—breast cancer	6.98e-06	0.000124	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CCND1—breast cancer	6.95e-06	0.000124	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—RELA—breast cancer	6.95e-06	0.000123	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—JUN—breast cancer	6.94e-06	0.000123	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—ERBB2—breast cancer	6.9e-06	0.000123	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CTNNB1—breast cancer	6.89e-06	0.000122	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IGF1—breast cancer	6.88e-06	0.000122	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—AKT2—breast cancer	6.87e-06	0.000122	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—EGFR—breast cancer	6.84e-06	0.000122	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PIK3CB—breast cancer	6.81e-06	0.000121	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—MTOR—breast cancer	6.81e-06	0.000121	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—MMP9—breast cancer	6.75e-06	0.00012	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CDKN1A—breast cancer	6.73e-06	0.00012	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PTEN—breast cancer	6.71e-06	0.000119	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PIK3CD—breast cancer	6.6e-06	0.000117	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—MAPK8—breast cancer	6.57e-06	0.000117	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—AKT1—breast cancer	6.55e-06	0.000116	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CXCL8—breast cancer	6.55e-06	0.000116	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—PIK3CA—breast cancer	6.54e-06	0.000116	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—SERPINE1—breast cancer	6.53e-06	0.000116	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—HRAS—breast cancer	6.5e-06	0.000116	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—KRAS—breast cancer	6.47e-06	0.000115	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CDKN1B—breast cancer	6.39e-06	0.000114	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—AKT1—breast cancer	6.32e-06	0.000112	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CASP3—breast cancer	6.26e-06	0.000111	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IL2—breast cancer	6.26e-06	0.000111	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—NOS3—breast cancer	6.24e-06	0.000111	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—SRC—breast cancer	6.22e-06	0.000111	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—IL6—breast cancer	6.22e-06	0.000111	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CCND1—breast cancer	6.1e-06	0.000108	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—JUN—breast cancer	6.08e-06	0.000108	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—VEGFA—breast cancer	6.06e-06	0.000108	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CTNNB1—breast cancer	6.04e-06	0.000107	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—STAT3—breast cancer	6e-06	0.000107	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—PIK3CA—breast cancer	5.94e-06	0.000106	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—MMP9—breast cancer	5.92e-06	0.000105	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—MDM2—breast cancer	5.92e-06	0.000105	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CDKN1A—breast cancer	5.9e-06	0.000105	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—RAF1—breast cancer	5.9e-06	0.000105	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PTEN—breast cancer	5.89e-06	0.000105	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—RELA—breast cancer	5.87e-06	0.000104	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—ERBB2—breast cancer	5.83e-06	0.000104	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—MAPK8—breast cancer	5.76e-06	0.000102	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—MTOR—breast cancer	5.76e-06	0.000102	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PIK3CB—breast cancer	5.76e-06	0.000102	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—AKT1—breast cancer	5.74e-06	0.000102	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—MAPK3—breast cancer	5.74e-06	0.000102	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—MYC—breast cancer	5.58e-06	9.92e-05	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—TGFB1—breast cancer	5.56e-06	9.89e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CXCL8—breast cancer	5.53e-06	9.83e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—HRAS—breast cancer	5.5e-06	9.77e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—SRC—breast cancer	5.46e-06	9.7e-05	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—EGFR—breast cancer	5.46e-06	9.7e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CDKN1B—breast cancer	5.4e-06	9.6e-05	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—AKT1—breast cancer	5.34e-06	9.5e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—VEGFA—breast cancer	5.32e-06	9.45e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CASP3—breast cancer	5.29e-06	9.41e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IL2—breast cancer	5.29e-06	9.4e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—STAT3—breast cancer	5.26e-06	9.36e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—IL6—breast cancer	5.26e-06	9.35e-05	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—KRAS—breast cancer	5.15e-06	9.16e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CCND1—breast cancer	5.15e-06	9.16e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—JUN—breast cancer	5.14e-06	9.14e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CTNNB1—breast cancer	5.1e-06	9.07e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—MAPK3—breast cancer	5.03e-06	8.94e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—MMP9—breast cancer	5e-06	8.9e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CDKN1A—breast cancer	4.99e-06	8.86e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PTEN—breast cancer	4.97e-06	8.84e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—MYC—breast cancer	4.89e-06	8.7e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—TGFB1—breast cancer	4.88e-06	8.67e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—MAPK8—breast cancer	4.87e-06	8.65e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—AKT1—breast cancer	4.85e-06	8.63e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—EGFR—breast cancer	4.78e-06	8.51e-05	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PIK3CA—breast cancer	4.74e-06	8.42e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—SRC—breast cancer	4.61e-06	8.2e-05	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—TP53—breast cancer	4.58e-06	8.14e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—KRAS—breast cancer	4.52e-06	8.03e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—VEGFA—breast cancer	4.49e-06	7.99e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—STAT3—breast cancer	4.45e-06	7.91e-05	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—HRAS—breast cancer	4.38e-06	7.79e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—MAPK3—breast cancer	4.25e-06	7.56e-05	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IL6—breast cancer	4.19e-06	7.45e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PIK3CA—breast cancer	4.15e-06	7.38e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—MYC—breast cancer	4.13e-06	7.35e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—TGFB1—breast cancer	4.12e-06	7.33e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—EGFR—breast cancer	4.04e-06	7.19e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—TP53—breast cancer	4.02e-06	7.14e-05	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—AKT1—breast cancer	3.87e-06	6.88e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—HRAS—breast cancer	3.84e-06	6.83e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—KRAS—breast cancer	3.82e-06	6.79e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IL6—breast cancer	3.68e-06	6.54e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PIK3CA—breast cancer	3.51e-06	6.24e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—TP53—breast cancer	3.39e-06	6.04e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—AKT1—breast cancer	3.39e-06	6.03e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—HRAS—breast cancer	3.25e-06	5.77e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IL6—breast cancer	3.11e-06	5.52e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—AKT1—breast cancer	2.87e-06	5.1e-05	CbGpPWpGaD
